Stem Cell Therapy vs Insulin Therapy: Comparing Long-Term Outcomes

Insulin and stem cell therapy are sometimes presented as competing diabetes treatments, but this comparison can be misleading.

Insulin is an established medicine that directly replaces or supplements a hormone needed to control blood glucose. It is essential for people with type 1 diabetes and may also be prescribed for type 2 or gestational diabetes.

“Stem cell therapy,” meanwhile, describes several very different experimental approaches. Some researchers are developing stem-cell-derived insulin-producing islet cells, primarily for type 1 diabetes. Other studies have investigated mesenchymal stem cells, or MSCs, in people with type 2 diabetes.

These interventions do not have the same mechanism, evidence base, regulatory status or long-term risks. Understanding those differences is essential before comparing outcomes.

Insulin is an established diabetes treatment, while most stem-cell approaches remain investigational and treatment-specific.

Quick Answer

Insulin has a well-established role in diabetes care and proven long-term benefits when used appropriately to manage blood glucose. Its main limitations include ongoing dosing, monitoring, hypoglycaemia risk, possible weight gain and the daily treatment burden.

Cell-based therapies may eventually reduce insulin requirements for carefully selected patients. Early stem-cell-derived islet studies in type 1 diabetes have produced encouraging results, including insulin independence in some participants. However, studies remain small, follow-up is limited and some approaches require lifelong immunosuppressive medication.

Mesenchymal stem-cell treatments studied for type 2 diabetes are different from insulin-producing islet replacement. Although some trials report improvements in HbA1c or insulin requirements, these treatments are not established replacements for insulin or other evidence-based diabetes care.

Key Takeaways

• Insulin remains essential for people with type 1 diabetes.

• Some—but not all—people with type 2 diabetes require insulin.

• “Stem cell therapy” covers several biologically different interventions.

• Stem-cell-derived islet therapies are mainly being developed for type 1 diabetes.

• Mesenchymal stem cells have also been investigated in type 2 diabetes, but evidence remains limited and heterogeneous.

• Early improvements do not establish lifelong effectiveness or safety.

• Some cell-replacement treatments require immunosuppressive medicines.

• FDA-approved donor-islet therapy exists for a narrow group of adults with type 1 diabetes, but it is not a stem-cell treatment.

• Insulin should never be stopped or reduced without supervision from the diabetes team.

• A commercial treatment should be compared with independent evidence and its regulatory status—not testimonials alone.

Table of Contents

1. Why This Is Not a Simple Treatment Comparison

2. How Does Insulin Therapy Work?

3. What Does Stem Cell Therapy for Diabetes Mean?

4. What Are the Long-Term Outcomes of Insulin Therapy?

5. What Do We Know About Cell-Therapy Outcomes?

6. How Do the Treatments Compare on Outcomes That Matter?

7. What Are the Risks?

8. What Should Patients Check Before Considering Treatment?

9. How A to Zen Therapies May Support Wellbeing

10. Frequently Asked Questions

Why This Is Not a Simple Treatment Comparison

Diabetes is not one condition. Our guide to diabetes types, symptoms and management explains why type 1, type 2, gestational and other forms of diabetes require different approaches.

Type 1 diabetes is an autoimmune condition in which the immune system destroys insulin-producing beta cells. The body therefore cannot produce enough insulin, making insulin treatment essential.

Type 2 diabetes usually involves insulin resistance together with a gradual loss of the pancreas’s ability to produce sufficient insulin. Treatment may involve nutrition and activity support, tablets, injectable medicines or insulin, depending on the person’s needs.

This distinction matters because most stem-cell-derived islet-replacement research focuses on type 1 diabetes. MSC studies in type 2 diabetes involve a different biological theory and should not be treated as evidence that stem cells can routinely replace insulin.

How Does Insulin Therapy Work?

Insulin allows glucose to move from the bloodstream into cells, where it can be used or stored. Treatment replaces insulin the body does not produce or provides additional insulin when natural production is insufficient.

The National Institute of Diabetes and Digestive and Kidney Diseases explains that people with type 1 diabetes must take insulin. Some people with type 2 diabetes also need it, either continuously or during particular circumstances such as pregnancy, serious illness or hospital treatment.

Insulin may be delivered using:

• A syringe

• An insulin pen

• An insulin pump

• An automated insulin-delivery system

• Inhaled insulin in selected adults

Treatment is individualised. Dose requirements can change with:

• Meals and carbohydrate intake

• Physical activity

• Illness or infection

• Stress

• Pregnancy

• Weight changes

• Other medication

• Blood-glucose patterns

People using insulin should follow the dosing and sick-day instructions provided by their diabetes team.

What Does Stem Cell Therapy for Diabetes Mean?

The term covers at least two distinct research directions.

Stem-Cell-Derived Islet Replacement

Scientists can develop stem cells into specialised islet cells capable of sensing glucose and producing insulin. These cells may then be transplanted into a person with type 1 diabetes.

The aim is to replace some of the beta-cell function lost through autoimmune destruction. Because donor or laboratory-derived cells can be attacked by the immune system, some recipients require immunosuppressive medicines.

Researchers are also exploring protective devices, modified cells and other methods intended to reduce or avoid immunosuppression. These strategies remain under investigation.

Mesenchymal Stem Cells for Type 2 Diabetes

MSCs are studied for their signalling and immunomodulatory effects rather than as direct replacements for insulin-producing beta cells.

Some studies have investigated whether MSC treatment could influence:

• Insulin sensitivity

• Inflammatory signalling

• Remaining beta-cell function

• HbA1c

• Insulin requirements

Research findings are not yet consistent enough to establish MSC treatment as standard care for type 2 diabetes. Studies differ in cell source, preparation, dosage, administration, participant selection and follow-up.

Therefore, results from a stem-cell-derived islet trial in type 1 diabetes cannot be used as proof that an MSC infusion treats type 2 diabetes—or vice versa.

What Are the Long-Term Outcomes of Insulin Therapy?

Insulin has been used clinically for more than a century. Its ability to reduce blood glucose is firmly established, and appropriate glucose management can help lower the risk of complications affecting the eyes, kidneys, nerves, heart and blood vessels.

Daily management may involve:

• Insulin injections or pump therapy

• Continuous or finger-prick glucose monitoring

• Mealtime dose calculations

• Correction doses

• Hypoglycaemia prevention

• Sick-day planning

• Regular HbA1c and complication checks

• Periodic adjustment of the treatment plan

This workload can be demanding, but modern technology may reduce some of the burden. Continuous glucose monitors, connected pens and automated insulin-delivery systems can provide more information and adjust insulin delivery more precisely.

Long-term outcomes depend on more than insulin alone. Access to monitoring technology, education, nutrition support, mental-health care and regular screening can all influence results.

Lifestyle changes may support blood-glucose management, particularly in type 2 diabetes, but they do not replace insulin when insulin is clinically required. Our guide to lifestyle habits and diabetes management explores this relationship in more detail.

Cell therapies progress through laboratory research, early human trials and long-term follow-up before entering routine care.

What Do We Know About Cell-Therapy Outcomes?

Approved Donor-Islet Therapy Is Not Stem Cell Therapy

In 2023, the FDA approved Lantidra, the first deceased-donor pancreatic-islet cellular

therapy for certain adults with type 1 diabetes who experience repeated severe hypoglycaemia despite intensive management.

This is an important development, but it requires several qualifications:

• The islets come from deceased donors, not stem cells.

• Eligibility is narrow.

• It is intended for selected adults with recurrent severe hypoglycaemia.

• The procedure carries risks.

• Recipients require immunosuppressive medication.

• Insulin independence is not guaranteed or necessarily permanent.

The FDA’s approval information and the NIDDK guide to pancreatic-islet transplantation explain who may be considered and why the treatment is not suitable for routine use in everyone with diabetes.

Stem-Cell-Derived Islets for Type 1 Diabetes

A 2025 early-phase study investigated zimislecel, an allogeneic stem-cell-derived islet therapy, in adults with type 1 diabetes and impaired awareness of hypoglycaemia.

Some participants achieved insulin independence during the reported follow-up. These findings are encouraging, but the study involved a small, highly selected group and used immunosuppressive treatment.

The peer-reviewed study published in the New England Journal of Medicine supports continued research. It does not yet establish lifelong effectiveness, widespread suitability or

superiority to modern insulin-delivery systems.

Questions still include:

• How long the transplanted cells remain functional

• Whether insulin independence persists

• How immune rejection can be prevented safely

• The long-term effects of immunosuppression

• Whether manufacturing can be scaled consistently

• Which patients are most likely to benefit

• How outcomes compare with automated insulin delivery

Mesenchymal Stem Cells for Type 2 Diabetes

Smaller clinical trials and reviews have reported possible improvements in HbA1c, C-peptide or insulin requirements following MSC-based interventions. However, methods and results vary considerably.

People researching stem cell for diabetes type 2 may encounter providers such as Swiss Medica, which describes an MSC-based approach. This information explains how that particular provider presents its programme, but it should be assessed alongside independent clinical evidence, regulatory information and advice from an endocrinologist who is not financially connected to the treatment.

Commercial availability does not establish that a treatment is approved, proven to prevent complications or equivalent to insulin. Patients should also confirm whether published studies examined the same cell source, preparation, dose and delivery method offered by the clinic.

📊 Evidence Snapshot

Treatment	Current role	Long-term evidence	Important limitations
Insulin therapy	Established treatment; essential in type 1 and used for selected type 2 diabetes	Extensive clinical experience and outcome data	Requires ongoing dosing and monitoring; hypoglycaemia and weight gain can occur
Automated insulin delivery	Established option for suitable people, mainly with type 1 diabetes	Growing evidence for improved time in range and reduced treatment burden	Device access, training, cost and continued insulin use
Deceased-donor islet therapy	Approved for a narrow group of adults with type 1 diabetes in some jurisdictions	Longer experience than stem-cell-derived islets, but limited eligibility	Donor supply, procedure risks and immunosuppression
Stem-cell-derived islet therapy	Experimental treatment mainly studied in type 1 diabetes	Encouraging early results; limited participant numbers and follow-up	Immunosuppression, durability, availability and long-term safety
MSC therapy for type 2 diabetes	Investigational	Some promising small studies, but evidence is heterogeneous	No established protocol, variable products and uncertain durability

How Do the Treatments Compare on Outcomes That Matter?

Blood-Glucose Control

Insulin has a predictable glucose-lowering action when the dose and timing are appropriate.

Cell therapies aim to change underlying beta-cell function or metabolic signalling. Responses may vary, and the effect of experimental treatment cannot currently be predicted with the same confidence.

Durability

Insulin continues working while it is used correctly, although the dose may need to change.

Cell-therapy durability depends on cell survival, immune response, disease progression and the intervention used. An improvement lasting several months is not the same as a lifelong cure.

Treatment Burden

Insulin can involve daily decisions, devices, injections and regular monitoring.

A cell treatment may involve fewer daily procedures if it works, but this must be balanced against preparation, travel, transplantation or infusion, follow-up, complications and possible immunosuppressive medication.

Quality of Life

Modern insulin technology may improve flexibility and reduce anxiety for some users. Others still experience substantial treatment burden or fear of hypoglycaemia.

A successful cell therapy could potentially reduce this burden. However, quality-of-life claims should come from validated patient-reported outcomes, not testimonials alone.

Prevention of Complications

Good glucose management with established diabetes care can reduce the risk of long-term complications.

Experimental cell therapies should not be assumed to protect the heart, kidneys, eyes, nerves or circulation unless clinical studies directly demonstrate those outcomes over an adequate period.

What Are the Risks?

Risks Associated With Insulin

The principal risks include:

• Hypoglycaemia

• Weight gain

• Injection-site reactions

• Lipohypertrophy from repeatedly injecting into the same area

• Dosing errors

• Device or infusion-set problems

• Emotional and practical treatment burden

Severe hypoglycaemia can cause confusion, seizures or loss of consciousness and requires immediate treatment.

Risks Associated With Cell-Based Treatment

Risks depend on the cell type and procedure but may include:

• Infection

• Bleeding or procedural complications

• Immune reactions

• Graft rejection

• Failure of the cells to function

• Abnormal tissue or cell growth

• Blood clots or infusion reactions

• Risks associated with immunosuppressive medication

• Unknown delayed effects

• Difficulty obtaining follow-up after overseas treatment

The FDA warns that unapproved regenerative products may expose patients to serious risks without reliable evidence of benefit. Its consumer alert on stem-cell and exosome products recommends confirming whether a product is approved or being administered within an authorised clinical trial.

💡 Expert Tip

Do not ask only, “Does the clinic offer stem cells?”

Ask for the exact product:

• What type of cells are used?

• Are they living cells?

• Where do they come from?

• How are they processed?

• What dose is administered?

• What is the intended mechanism?

• Which published trial studied that exact product?

• Is the treatment authorised for diabetes in that country?

• Is it part of a registered clinical trial?

“Stem cell therapy” is too broad a term to establish evidence or safety.

What Should Patients Check Before Considering Treatment?

Before paying for an experimental programme, request written answers to the following questions:

1. Is the treatment intended for type 1 or type 2 diabetes?

2. What exact cell product will be administered?

3. Is it approved for this indication?

4. Is there a publicly registered clinical trial?

5. Have results been published in a peer-reviewed journal?

6. How many participants received the same product?

7. How long were they followed?

8. Were outcomes compared with standard care?

9. How many became insulin independent—and for how long?

10. Is immunosuppression required?

11. What complications have occurred?

12. Who manages emergencies after the patient returns home?

13. What follow-up tests are included?

14. Will the clinic communicate with the patient’s endocrinologist?

15. What happens if the treatment does not work?

Our guide to reading emerging wellness research without falling for the hype can help patients distinguish biological plausibility from proven clinical benefit.

Myth Versus Fact

Myth: Stem cells can already cure diabetes.

Fact: Some cell therapies may restore insulin production in selected research participants, but no stem-cell treatment is an established universal cure for type 1 or type 2 diabetes.

Myth: Lantidra proves that stem-cell therapy works.

Fact: Lantidra uses pancreatic islets from deceased donors. It is not derived from stem cells and is approved only for a narrowly defined type 1 diabetes population.

Myth: Becoming insulin independent means diabetes is permanently cured.

Fact: Cell function may decline, autoimmune processes may persist and treatment effects may not be lifelong.

Myth: Insulin represents treatment failure in type 2 diabetes.

Fact: Type 2 diabetes changes over time. Insulin may be the safest and most effective option when the body can no longer produce enough.

Myth: A personalised stem-cell protocol is automatically evidence based.

Fact: Personalisation does not replace controlled research, transparent product information or regulatory oversight.

How A to Zen Therapies May Support Wellbeing

A to Zen Therapies does not diagnose diabetes, change diabetes medication or provide stem-cell treatment.

Some people with diabetes use massage therapy or acupuncture as part of a wider relaxation and wellbeing routine. These services do not lower HbA1c directly or replace medication, monitoring, nutrition support or endocrinology care.

Tell the practitioner if you have:

• Neuropathy or reduced sensation

• Poor circulation

• Broken or fragile skin

• Foot wounds

• Unexplained swelling

• Recent severe hypoglycaemia

• An insulin pump or continuous glucose monitor

• Injection or infusion sites that must be avoided

Treatment may need to be adapted or postponed where blood glucose is unstable, circulation is poor or skin integrity is compromised.

Frequently Asked Questions

Is Stem Cell Therapy Better Than Insulin?

There is not enough evidence to make that general claim. Insulin is established and essential for type 1 diabetes. Cell therapies remain treatment-specific, experimental or restricted to narrow patient groups.

Can Stem Cells Eliminate the Need for Insulin?

Some participants in early type 1 diabetes islet-cell studies have achieved insulin independence. This is not guaranteed, may not be permanent and may require immunosuppressive medication.

Is Stem Cell Therapy Approved for Type 2 Diabetes?

MSC and other stem-cell interventions are being studied, but they are not established replacements for standard type 2 diabetes treatment. Approval varies by jurisdiction and exact product. Patients should verify the status with the relevant national regulator.

Can Someone Stop Insulin After Cell Therapy?

Not without direct supervision from the diabetes team. Stopping insulin prematurely can cause severe hyperglycaemia or diabetic ketoacidosis.

What Is the Difference Between Islet Cells and Stem Cells?

Islet cells are specialised pancreatic cells that include insulin-producing beta cells. Stem cells are less specialised cells that may be developed into different cell types. Donor-islet transplantation and stem-cell-derived islet therapy are therefore not identical.

Does Stem Cell Therapy Treat Diabetes Complications?

This should not be assumed. Claims involving neuropathy, kidney disease, circulation or cardiovascular protection require separate evidence. Better glucose readings alone do not prove that established complications have been reversed.

How Can I Find a Legitimate Clinical Trial?

Search an official registry such as ClinicalTrials.gov and discuss the study with an independent endocrinologist. A listing confirms registration, not that a treatment has already been proven effective.

What the Evidence Means for Long-Term Treatment

Stem cell therapy versus insulin therapy is not currently a comparison between two equally established choices.

Insulin has a defined role, extensive clinical experience and predictable glucose-lowering effects. Its burden and risks are real, but clinicians understand how to monitor and adjust it.

Cell therapies represent several developing strategies. Stem-cell-derived islets may eventually reduce insulin dependence for some people with type 1 diabetes. MSC interventions are also being investigated in type 2 diabetes. Nevertheless, early promise must be separated from proven durability, regulatory approval and protection from long-term complications.

People considering treatment should not stop prescribed medication or rely solely on information from a commercial provider. The safest approach is to compare the exact intervention with independent evidence and discuss it with a diabetes specialist who can evaluate the risks in the context of the patient’s health.

Continue Exploring Hormone and Metabolic Health

For more background, read Understanding Diabetes: Types, Symptoms and Management.

You can also explore the Hormone Health Hub and Nutrition Hub for evidence-informed guidance on metabolic health, nutrition and treatment decisions.

References

1. NIDDK — Insulin, Medicines and Other Diabetes Treatments

2. NIDDK — Pancreatic Islet Transplantation

3. FDA — First Cellular Therapy for Selected Patients With Type 1 Diabetes

4. FDA — Consumer Alert on Regenerative Medicine Products

5. New England Journal of Medicine/PubMed — Stem-Cell-Derived Fully Differentiated Islets for Type 1 Diabetes

6. ClinicalTrials.gov — Clinical Trial Registry